Navigate this market better. Subscribe for FREE stock alerts and information.

Tuesday, June 10, 2014

Allergan rejects Valeant and Ackman's raised takeover offer, (NYSE: AGN), (NYSE: VRX), (TSE: VRX.TO)

Botox maker Allergan Inc on Tuesday rejected a sweetened $53 billion takeover offer from Valeant Pharmaceuticals International and activist investor William Ackman, reiterating that it undervalues the company and is too risky for shareholders.Valeant and Pershing Square Capital Management made a joint bid for the company on April 22 that Allergan also had declined, saying that its plans to slash spending would cost the company growth. It has so far refused to enter deal discussions."I think from the first rejection Allergan seemed pretty set on not going forward with the deal and delaying any negotiations or shareholder vote," said Michael Waterhouse, analyst at Morningstar Research.Ackman, who runs Pershing and has almost a 10 percent stake in Allergan, and Valeant raised their joint offer on May 28 and when investors were displeased and sold shares, added even more cash to it on May 30.

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN fell by 0.66% or $-1.09/share to $163.06. In the past year, the shares have traded as low as $81.33 and as high as $172.48. On average, 4636580 shares of AGN exchange hands on a given day and today's volume is recorded at 1661915.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 1.64% or $-2.08/share to $124.55. In the past year, the shares have traded as low as $81.94 and as high as $153.10. On average, 3271970 shares of VRX exchange hands on a given day and today's volume is recorded at 1524221.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 1.48% or $-2.04/share to $135.99. In the past year, the shares have traded as low as $83.39 and as high as $170.45. On average, 372252 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 127971.



Source